Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

BLADDER CANCER

Pembrolizumab use in bladder cancer: a tale of two trials

Nature Reviews Urology volume 18, pages 577–578 (2021)Cite this article

Subjects

The treatment of patients with the PD1 inhibitor pembrolizumab yields benefit in the second-line metastatic urothelial cancer setting. Two new trials have studied pembrolizumab monotherapy in other patients with urothelial carcinoma: an open-label phase II trial has enrolled patients with high-risk BCG-refractory non-muscle-invasive disease, and a phase III trial has compared three first-line treatment options for patients with metastatic disease. However, these trials have shown conflicting results.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).

    Article  CAS  Google Scholar 

  2. Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483–1492 (2017).

    Article  CAS  Google Scholar 

  3. O’Donnell, P. H. et al. First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): response and survival results up to five years from the KEYNOTE-052 phase 2 study. J. Clin. Oncol. 39 (Suppl. 15), 4508 (2021).

    Article  Google Scholar 

  4. Powles, T. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 931–945 (2021).

    Article  CAS  Google Scholar 

  5. Balar, A. V. et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 22, 919–930 (2021).

    Article  CAS  Google Scholar 

  6. Galsky, M. D. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395, 1547–1557 (2020).

    Article  CAS  Google Scholar 

  7. FDA. FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy to treat urothelial cancer with low expression of PD-L1. FDA https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-and-oncology-clinical-investigators-about-efficacy-issue (2018).

  8. FDA. April 27-29, 2021: meeting of the Oncologic Drugs Advisory Committee meeting announcement. FDA https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-27-29-2021-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04272021-04292021#event-materials (2021).

  9. Hanna, N. H. et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J. Clin. Oncol. 39, 1040–1091 (2021).

    Article  Google Scholar 

  10. Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102–2114 (2021).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA

    Jeanny B. Aragon-Ching

Authors
  1. Jeanny B. Aragon-Ching
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeanny B. Aragon-Ching.

Ethics declarations

Competing interests

J.B.A.-C. serves in the Speakers’ Bureau for Bristol-Myers Squibb and serves on the advisory board of Pfizer, Merck and EMD Serono.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aragon-Ching, J.B. Pembrolizumab use in bladder cancer: a tale of two trials. Nat Rev Urol 18, 577–578 (2021). https://doi.org/10.1038/s41585-021-00499-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-021-00499-5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer